AACR 2012: AZD3514 in Prostate Cancer
The 2012 annual meeting of the American Association for Cancer Research (AACR) provided a window into the world of new cancer drugs in early development. One that caught my attention in prostate cancer was AstraZeneca's AZD3514, a first-in-class Androgen Receptor down-regulator (SARD).
- — inThought Team (@in_Thought)Tue, Apr 03 2012 15:00:48
Did you find this story interesting? Be the first to like or comment.